Press Releases & Announcements

A5349: RIFAPENTINE-CONTAINING TREATMENT SHORTENING REGIMENS FOR PULMONARY TUBERCULOSIS

Oct 20, 2021

A5336: A RANDOMIZED, PILOT STUDY OF RUXOLITINIB IN ANTIRETROVIRAL-TREATED HIV-INFECTED ADULTS

Oct 20, 2021

A5333S: MECHANISTIC SUB-STUDY OF A5332: RANDOMIZED TRIAL TO PREVENT VASCULAR EVENTS IN HIV (REPRIEVE)

Oct 20, 2021

ACTG TO PRESENT DATA ON INVESTIGATIONAL NEW COVID-19 TREATMENT AT IDWEEK 2021

Sep 29, 2021

ACTG ANNOUNCES GRADUATION OF NOVEL POLYCLONAL ANTIBODY THERAPY SAB-185 TO PHASE 3 STUDY IN ACTIV-2

Sep 27, 2021

ACTG ANNOUNCES DATA FROM ACTIV-2 STUDY, DEMONSTRATING BENEFIT OF BRII-196 AND BRII-198 IN NON-HOSPITALIZED PARTICIPANTS WITH COVID-19

Aug 26, 2021

ACTG NETWORK SOLICITS FOR MEMBERSHIP TO ITS SCIENCE COMMITTEES

Aug 25, 2021

SMALL CLINICAL TRIALS ADVANCING HIV REMISSION AND CURE - DUE SEPTEMBER 1, 2021

Aug 13, 2021

ACTG LAUNCHES STUDY EVALUATING THE EFFECTS OF AN ARV CHANGE AMONG PEOPLE LIVING WITH HIV WHO EXPERIENCE EXCESSIVE WEIGHT GAIN

Jul 29, 2021

SOLICITATION FOR ACTG SCIENCE COMMITTEE LEADERSHIP POSITIONS

Jul 27, 2021

ACTG ANNOUNCES PUBLICATION OF REPRIEVE SUB-STUDY IN JAMA NETWORK OPEN, PROVIDING INSIGHTS INTO CARDIOVASCULAR DISEASE RISK AMONG PEOPLE LIVING WITH HIV

Jun 30, 2021

ACTG ANNOUNCES CAMOSTAT WILL NOT ADVANCE TO PHASE 3 IN OUTPATIENT TREATMENT STUDY FOR COVID-19

Jun 30, 2021